Trials that use: Multiplicity adjustment
New to this method? Read the tutorial →
20,317 results
- PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A: Complete Statistical AnalysisIndependent statistical analysis of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02492984).
- PF-06669571 In Subjects With Idiopathic Parkinson’s Disease: Complete Statistical AnalysisIndependent statistical analysis of PF-06669571 In Subjects With Idiopathic Parkinson's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02565628).
- PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03685591).
- PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): Complete Statistical AnalysisIndependent statistical analysis of PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05780541).
- PFA and SPFIndependent statistical analysis of Determination of Sun Protection in Sunscreen Formulas (Study SR09-15)(P08236)(COMPLETED): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01001975).
- PFAS Exposure and Immune Response to Vaccination in Adults: Complete Statistical AnalysisIndependent statistical analysis of PFAS Exposure and Immune Response to Vaccination in Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06588530).
- PFPSIndependent statistical analysis of Effectiveness Trial for Evaluating IAHA for PFPS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01811654).
- PG3TIndependent statistical analysis of Polidocanol Versus Glucose Treatment of Telangiectasia Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02657252).
- PGAIndependent statistical analysis of (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01936974).
- Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph I/II Nab-Paclitaxel & Carboplatin w/Concurrent Radiation Therapy for Unresectable Stg III NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: Complete Statistical AnalysisIndependent statistical analysis of Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00280735).
- Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: Complete Statistical AnalysisIndependent statistical analysis of Ph II Erlotinib + Sirolimus for Pts w Recurrent Malignant Glioma Multiforme: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: Complete Statistical AnalysisIndependent statistical analysis of Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00590902).
- Ph II Study of Azacitidine in Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Ph II Study of Azacitidine in Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00569660).
- PH-HFpEFIndependent statistical analysis of Oral Nitrite in Patients With Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM: Complete Statistical AnalysisIndependent statistical analysis of Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00597493).
- Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin: Complete Statistical AnalysisIndependent statistical analysis of Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin: primary endpoint results, effect estimate with confidence interval, sample-size…
- Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell: Complete Statistical AnalysisIndependent statistical analysis of Ph2 Gem/Nov/Rituxan Rel/Ref MantleCell: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00656084).
- Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure: Complete Statistical AnalysisIndependent statistical analysis of Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- PhantomLimbIndependent statistical analysis of Epidural Spinal Cord Stimulation for Sensory Restoration and Phantom Limb Pain in Upper-Limb Amputees: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- PHARLAPIndependent statistical analysis of Open Lung Ventilation in ARDS: The PHARLAP Trial: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01667146).
- Pharmacist Intervention to Improve Smoking Cessation: Complete Statistical AnalysisIndependent statistical analysis of Pharmacist Intervention to Improve Smoking Cessation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT06943287).
- Pharmacist Intervention to Reduce Post-Hospitalization Utilization: Complete Statistical AnalysisIndependent statistical analysis of Pharmacist Intervention to Reduce Post-Hospitalization Utilization: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04071951).
- Pharmacist Provision of Medication Abortion: Complete Statistical AnalysisIndependent statistical analysis of Pharmacist Provision of Medication Abortion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04956731).
- Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy: Complete Statistical AnalysisIndependent statistical analysis of Pharmacists and Pharmacy Technicians to Improve Admission Medication History Accuracy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02026453).
- Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic Biomarkers to Support Biosimilar Development: Interferon Beta-1A Products: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04183491).
- Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic Biomarkers to Support Biosimilar Development: PCSK9 Inhibitors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04189484).
- Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01852214).
- Pharmacodynamic Evaluation of Intranasal Nalmefene: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic Evaluation of Intranasal Nalmefene: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04828005).
- Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamic Study of AZD1722 in End-stage Renal Disease Patients on Hemodialysis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamics, Safety and Pharmacokinetics of BMS-663068, an HIV Attachment Inhibitor, in HIV-1: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: Complete Statistical AnalysisIndependent statistical analysis of Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED): Complete Statistical AnalysisIndependent statistical analysis of Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED): primary endpoint results, effect estimate…
- Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02884908).
- Pharmacogenetics of Alcohol: Treatment Implications: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics of Alcohol: Treatment Implications: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00734656).
- Pharmacogenetics of Doxazosin for Cocaine Dependence: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics of Doxazosin for Cocaine Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01145183).
- Pharmacogenetics of Nicotine Addiction Treatment: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics of Nicotine Addiction Treatment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01314001).
- Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics to Predict Drug Interactions in Kidney Transplant Recipients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01288521).
- Pharmacogenetics, Emotional Reactivity and Smoking: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenetics, Emotional Reactivity and Smoking: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00507728).
- Pharmacogenomic Testing in Primary Care: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenomic Testing in Primary Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03270891).
- Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenomics and Pharmacometabolomics of Acamprosate Treatment Outcome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03818191).
- Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids: Complete Statistical AnalysisIndependent statistical analysis of Pharmacogenomics of the Variability in the In Vivo Response to Glucocorticoids: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic (PK) and Tolerance Study of Natroba Topical Suspension in Pediatrics With an Active Head Lice Infestation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01491113).
- Pharmacokinetic Alterations During ECMO: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic Alterations During ECMO: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01938079).
- Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic and Exploratory Electrocardiogram (ECG) Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01018420).
- Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic and Pharmacodynamic Effects of Passive Cannabis Inhalation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01798186).
- Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF: Complete Statistical AnalysisIndependent statistical analysis of Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01937130).